• Home
  • NEW DAY MEDICINE
  • 6 (68) 2024
  • 46 -6 (68) 2024 - Tolibov F.F. - VIOLATION OF PLATELET AGGREGATION AND IMBALANCE OF HEMOSTASIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

46 -6 (68) 2024 - Tolibov F.F. - VIOLATION OF PLATELET AGGREGATION AND IMBALANCE OF HEMOSTASIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

VIOLATION OF PLATELET AGGREGATION AND IMBALANCE OF HEMOSTASIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C

Tolibov F.F. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

A study investigated the blood clotting and platelet function in patients with chronic hepatitis C (CHC) infection. The study included 82 CHC patients (39 with advanced liver fibrosis and 43 with no or mild liver fibrosis) and 39 healthy individuals. 33 patients were treated and achieved sustained virological response (SVR). Blood samples were collected before and after treatment. The study found that CHC patients with advanced fibrosis had impaired platelet function and lower levels of antithrombin, platelet count, and coagulation factors II-VII-X compared to healthy individuals. However, thromboelastography (TEG) did not differ between the groups. In patients who achieved SVR, post-treatment platelet count was higher than pre-treatment counts and some measures of platelet function improved, but remained below levels in healthy individuals. The study suggests that CHC-infected patients exhibit rebalanced blood clotting with only partial normalization in patients achieving SVR, which may have implications for the risk of cardiovascular disease and bleeding. Further studies are needed to understand the implications of rebalanced blood clotting.

Keywords: HCV, hemostasis, platelet aggregation

First page

264

Last page

268

For citation:Tolibov F.F. - VIOLATION OF PLATELET AGGREGATION AND IMBALANCE OF HEMOSTASIS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS C//New Day in Medicine 6(68)2024 264-268 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Ampuero J. Assessing cardiovascular risk in hepatitis c: An unmet need. //World J. Hepatol. 2015;7:2214.
  2. Butt A.A., Wang X., Budoff M., Leaf D., Kuller, L.H., Justice, A.C. Hepatitis c virus infection and the risk of coronary disease. //Clin. Infect. Diseases 2011;49:225-232.
  3. Chen S.L.; Morgan T.R. The natural history of hepatitis c virus (HCV) infection. //Int. J. Med. 2006;3:47-52.
  4. Clin. Gastroenterol. Hepatol. 2013;11:1064-1074.
  5. Fouad Y.M. Chronic hepatitis c-associated thrombocytopenia: Aetiology and management. Trop. //Gastroenterol. 2013;34:58-67.
  6. World Health Organization (WHO). Hepatitis C; WHO: Geneva, Switzerland, 2014.
  7. Jumayeva M.F., Predictors of The Development Of Hepatorenal Syndrome. //Problems biology and medicine. 2022;6(140):80-82.
  8. Jumaeva M.F., Hepatorenal Syndrome. //Asian journal of Pharmaceutical and biological research. SEPT.-DEC. 2022;11(3):72-77.
  9. Jumayeva M.F. Hepatocardiorenal syndrome. //Asian journal of Pharmaceutical and biological research. JAN-APR 2022;11(1).
  10. Jumaeva M.F., Gepatokardiorenal sindrom. //Farmatsevtika va biologik tadqiqotlar Osiyo jurnali. 2022 YAN-APRAL;11(1):83-97.
  11. Jumaeva MF, Gepatorenal sindrom. //Farmatsevtika va biologik tadqiqotlar Osiyo jurnali. SENTYABR-DEK. 2022;11(3):72-77.
  12. Jumayeva MF, Gepatorenal sindrom rivojlanishining prognozchilari. //Biologiya va tibbiyot muammolari. 2022;6(140):80-82.
  13. Lisman T.; Leebeek F.W.G. Hemostatic alterations in liver disease: A review on pathophysiology, clinical consequences, and treatment. //Dig. Surg. 2007;24:250-258.
  14. Lisman T. Hemostatic dysfunction in liver diseases. //Semin. Thromb. Hemost. 2015;445-446.
  15. Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: Evidence and clinical consequences. //Blood 2010;116:878-885.
  16. Lisman T.; Bongers T.N., Adelmeijer J., Janssen H.L.A., de Maat, M.P.M., de Groot P.G., Leebeek F.W.G. Elevated levels of von willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. //Hepatology 2006;44:53-61.
  17. Northup P.G., Caldwel S.H. Coagulation in liver disease: A guide for the clinician.
  18. Sherman K.E. Advanced liver disease: What every hepatitis c virus treater should know. //Top. Antivir. Med. 2011;19:121-125.
  19. Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease. //N. Engl. J. Med. 2011;365:147-156.
  20. Zampino R., Marrone A., Restivo L., Guerrera B., Sellitto A., Rinaldi L., Romano C., Adinolfi L.E. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. //World J. Hepatol. 2013;5:528-540.

    file

    download